公司资料
Prime Medicine 股价、新闻与催化剂
- 股票代码:
- PRME
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
3.17 USD (+2.59%)
收盘价
最后更新: 2026年8月17日
580M USD
市值
股价为何变动
As of Aug 17, 2026, PRME closed up 2.59% at $3.17. No new same-company headline was identified in the current news window.
公司概览
Prime Editing
Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo.
PM577
PM577 is an in vivo Prime Editing candidate designed to correct disease-causing mutations in the liver for Wilson disease.
PM647
PM647 is an in vivo liver-directed program for alpha-1 antitrypsin deficiency and is approaching clinical development on a timeline similar to PM577.
Chronic Granulomatous Disease
PM359 is an ex vivo edited cell therapy for chronic granulomatous disease. Prime Medicine is continuing regulatory dialogue with the FDA regarding a potential BLA path.
未来催化剂
- IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026.
- IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026.
- Initial clinical data from PM577 and PM647 in 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。